Skip to main content

This site is intended for US residents.

OJEMDA (tovorafenib) logo: 100 mg tablets 25 mg/mL for oral suspension

Joseph, lives with pLGG

Educational
resources

Discover more about OJEMDA

Whether you are exploring treatment options for pLGG or your child has recently been prescribed OJEMDA, it's important to be prepared and make a plan in partnership with your child's care team. The resources below can help you at any stage along the treatment journey. 

Are you considering talking to your child’s doctor about OJEMDA?

Doctor Discussion Guide

This resource provides a list of questions to begin an open dialogue about OJEMDA and whether it might be right for your child.

Download

A Guide for Considering OJEMDA

Explore clinical trial results, possible side effects, and available patient support tailored to your family's needs.

Download

Watch: Understanding OJEMDA—What Families Should Know

Hear from a pediatric hematology oncologist and a caregiver navigating pLGG. This educational webinar dives deeper into how OJEMDA works, clinical trial results and learnings, and the ways in which EveryDay Support From Day One™ can help you and your family.

Sign up to watch

Has your child been prescribed OJEMDA?

What to Know When Starting OJEMDA

Just beginning once-a-week OJEMDA? Learn more about how to take OJEMDA, treatment routine tips, and potential side effects and how to manage them.

Download

A Guide to Learning About Side Effects of OJEMDA

Are you preparing for potential side effects with OJEMDA? This in-depth guide will walk you through exactly what side effects to expect and provide comprehensive tips to manage some of them.

Download

Step-by-Step Guide for Preparing a Liquid Dose of OJEMDA

Need to learn how to prepare and give a liquid dose to your child? Master the step-by-step process for preparing your child's liquid medicine with this guide.

Download

Watch: The Instructional Video for Preparing a Liquid Dose of OJEMDA

The video and step-by-step guide for preparing a liquid dose of OJEMDA allow you to learn in the style you choose.

Watch the video

EveryDay Support From Day One™ Brochure

Want to learn more about available support for patients taking OJEMDA? This brochure has all you need to know about EveryDay Support From Day One.

Download

Sign up

IMPORTANT SAFETY
INFORMATION

Before taking or giving OJEMDA, tell your healthcare provider about all of your or your child’s medical conditions, including if you:

  • have bleeding, skin, or liver problems
  • are pregnant or plan to become pregnant. OJEMDA can harm your unborn baby.

Females who are able to become pregnant:

  • You should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 28 days after your last dose of OJEMDA.

Males with female partners who are able to become pregnant should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 2 weeks after your last dose of OJEMDA.

  • are breastfeeding or plan to breastfeed. Do not breastfeed during treatment and for 2 weeks after your last dose of OJEMDA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking certain other medicines can affect how OJEMDA works and may increase your risk of side effects. OJEMDA may also affect how other medicines work.

What should I avoid while taking OJEMDA?

Limit the amount of time you spend in sunlight. OJEMDA can make your skin sensitive to the sun (photosensitivity). Use sun protection measures, such as sunscreen, sunglasses and wear protective clothes that cover your skin during your treatment with OJEMDA.

What are the possible side effects of OJEMDA?

OJEMDA may cause serious side effects, including:

  • bleeding problems (hemorrhage) are common and can also be serious. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:
    • headache, dizziness or feeling weak
    • coughing up blood or blood clots
    • vomiting blood or your vomit looks like "coffee grounds"
    • red or black stools that look like tar
  • skin reactions, including sensitivity to sunlight (photosensitivity). OJEMDA can cause skin reactions that can become severe. Tell your healthcare provider if you get new or worsening skin reactions, including:
    • rash
    • bumps or tiny papules
    • acne
    • peeling, redness, or irritation
    • blisters
  • liver problems. Your healthcare provider will do blood tests to check your liver function before and during treatment with OJEMDA. Tell your healthcare provider right away if you develop any of the following symptoms:
    • yellowing of your skin or your eyes
    • dark or brown (tea-colored) urine
    • nausea or vomiting
    • loss of appetite
    • feeling tired
    • bruising
    • bleeding
    • pain in your upper right stomach area
  • slowed growth in children. Growth will be checked routinely during treatment with OJEMDA.

The most common side effects of OJEMDA include:

  • rash
  • hair color changes
  • feeling tired
  • viral infection
  • vomiting
  • headache
  • fever
  • dry skin
  • constipation
  • nausea
  • acne
  • upper respiratory tract infection

OJEMDA may cause fertility problems in males and females, which may affect your ability to have children.

These are not all the possible side effects of OJEMDA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Day One Biopharmaceuticals at 1-877-204-2820.

Please see full Patient Information, including Instructions for Use for more information.

INDICATION

What is OJEMDA™ (tovorafenib)?

OJEMDA is a prescription medicine used to treat certain types of brain tumors (cancers) called gliomas in people 6 months and older:

  • that is a pediatric low-grade glioma (LGG), and
  • that has come back after previous treatment or has not responded to previous treatment and
  • that has a certain type of abnormal BRAF gene.